Palisade Bio's PALI-2108 Demonstrates Local Bioactivation And Dose Dependent Efficacy Response In Preclinical Mouse Models

5/21/24 8:41:08 AM ET

$PALI

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $PALI alert in real time by email

Data presented at Digestive Disease Week (DDW) 2024

Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure

PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patients

Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of UC before year end

Get the next $PALI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PALI

Date	Price Target	Rating	Analyst
2/2/2022	$5.00	Buy	Ladenburg Thalmann
8/31/2021	$7.00	Buy	Maxim Group

More analyst ratings

$PALI
Press Releases

Fastest customizable press release news feed in the world

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preclinical results for PALI-2108, a novel local PDE4 inhibitor prodrug. In recent studies using the Dextran Sulfate Sodium (DSS) colitis mouse model, PALI-2108 demonstrated a dose-dependent effect on key fibrotic pathways, underscoring its
11/21/24 8:15:00 AM ET
$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
Presentation to highlight advances in fibrostenotic Crohn's Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic disease, today announced that it has been invited to present at the 8th Annual Antifibrotic Drug Development (AFDD) Summit, being held November 19-21, 2024, in Boston, MA. Details of the presentation details are as follows: Title: Detailing Characteristics of Fibrostenotic Crohn's Disease Biology
11/14/24 9:00:00 AM ET
$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the third quarter of 2024 and provided a business update. Recent Highlights Commenced enrollment and dosed first subjects in its Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-sev
11/12/24 8:45:00 AM ET
$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Palisade Bio Appoints Margery Fischbein to its Board of Directors
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma
5/7/24 8:30:00 AM ET
$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20
2/8/24 2:40:00 PM ET
$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD, Associate Staff in the Department of Gastroenterology, Hepatology, and Nutrition, as well as an Investigator in the Department of Pathobiology at the Cleveland Clinic Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinic
2/8/24 8:05:00 AM ET
$PALI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Palisade Bio's PALI-2108 Demonstrates Local Bioactivation And Dose Dependent Efficacy Response In Preclinical Mouse Models

Chat with this insight

Recent Analyst Ratings for $PALI

$PALI Press Releases

Fastest customizable press release news feed in the world

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

$PALI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

$PALI Market Insights

Live Market Insights

Palisade Bio shares are trading higher after the company announced that European Patent Office has issued a decision to grant notice for patent number 4,157,853 titled, "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors."

Palisade Bio Announces European Patent Office Issued Decision To Grant Notice For Patent Number 4,157,853 Titled "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors."

Palisade Bio shares are trading higher after the company announced the completion of the first Good Manufacturing Practice batch of its drug substance PALI-2108 and is on track to commence its Phase 1 human clinical study.

$PALI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Wei Binxian

SEC Form 4 filed by Director Fischbein Margery B.

SEC Form 4 filed by Director Williams Donald Allen

$PALI Leadership Updates

Live Leadership Updates

$PALI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

Maxim Group initiated coverage on Palisade Bio with a new price target

$PALI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Palisade Bio Inc.

SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

$PALI Financials

Live finance-specific insights

$PALI SEC Filings

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

Amendment: SEC Form S-1/A filed by Palisade Bio Inc.

SEC Form 10-Q filed by Palisade Bio Inc.

SEC Form S-1 filed by Palisade Bio Inc.

Recent Analyst Ratings for
$PALI

$PALI
Press Releases

$PALI
Insider Purchases

$PALI
Market Insights

$PALI
Insider Trading

$PALI
Leadership Updates

$PALI
Analyst Ratings

$PALI
Large Ownership Changes

$PALI
Financials

$PALI
SEC Filings